comparemela.com

Latest Breaking News On - International prognostic index - Page 1 : comparemela.com

Tucidinostat Plus R-CHOP Improves EFS in DLBCL Expressing MYC and BCL2

Tucidinostat plus R-CHOP improved efficacy and was safe in previously untreated DLBCL expressing MYC and BCL2.

Weili zhaoShanghai institute of hematologyKey laboratory of medical genomicsInternational prognostic indexNational research centerShanghai instituteState key laboratoryMedical genomicsTranslational medicineRuijin hospital affiliatedShanghai jiao tong university school

Adding Ibrutinib to Chemoimmunotherapy Induction Improves FFS in Younger MCL

The addition of ibrutinib to chemoimmunotherapy induction with ASCT improved rates of failure-free survival in younger patients with mantle cell lymphoma.

Martin dreylingUniversity hospital munichInternational prognostic indexDepartment of internal medicinePrognostic indexInternal medicineHospital munichAnn arbor

How Does Metabolic Tumor Volume Affect Responses to Axi-Cel in LBCL?

The authors say a standard method of assessing metabolic tumor volume would be needed for its use to become widespread.

Fred lockeFrederick lockeH lee moffitt cancer centerInternational prognostic indexMoffitt cancer centerMoffitt cancer

Follicular Lymphoma - Causes, Symptoms, Diagnosis, Treatment and Prevention

Follicular Lymphoma - Causes, Symptoms, Diagnosis, Treatment and Prevention
medindia.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medindia.net Daily Mail and Mail on Sunday newspapers.

Health tipsInternational prognostic indexFollicular lymphoma international prognostic indexComputed tomography

Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL

Hayder Saeed, MD, discusses key takeaways regarding the use of polatuzumab vedotin plus R-CHP in diffuse large B-cell lymphoma.

Hayder saeedInternational prognostic indexMoffitt cancer centerMalignant hematologyBridging the gapsHematologic malignancies

vimarsana © 2020. All Rights Reserved.